Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F23%3A10466457" target="_blank" >RIV/00064165:_____/23:10466457 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10466457
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=tN1mw3Xp5W" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=tN1mw3Xp5W</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00415-023-11615-3" target="_blank" >10.1007/s00415-023-11615-3</a>
Alternative languages
Result language
angličtina
Original language name
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS
Original language description
Background: While immediate benefits of levodopa-carbidopa intestinal gel (LCIG) are evident in patients with Parkinson's disease (PD), long-term LCIG effects require further study. Objectives: We explored long-term LCIG on motor symptoms, nonmotor symptoms (NMS), and LCIG treatment settings in patients with advanced PD (APD). Methods: Data were obtained (medical records and patient visit) from COSMOS, a multinational, retrospective, cross-sectional post-marketing observational study in patients with APD. Patients were stratified into 5 groups based on LCIG treatment duration at the patient visit, from 1-2 to > 5 years LCIG. Between-group differences were assessed for changes from baseline in LCIG settings, motor symptoms, NMS, add-on medications, and safety. Results: Out of 387 patients, the number of patients per LCIG group was: > 1- <= 2 years LCIG (n = 156); > 2- <= 3 years LCIG (n = 80); > 3- <= 4 years LCIG (n = 61); > 4- <= 5 years LCIG (n = 30); > 5 years LCIG (n = 60). Baseline values were similar; data reported are changes from the baseline. There were reductions in "off" time, dyskinesia duration, and severity across LCIG groups. Prevalence, severity, and frequency of many individual motor symptoms and some NMS were reduced amongst all LCIG groups, with few differences between groups. Doses for LCIG, LEDD and LEDD for add-on medications were similar across groups both at LCIG initiation and patient visit. Adverse events were similar across all LCIG groups and consistent with the established safety profile of LCIG. Conclusions: LCIG may provide sustained, long-term symptom control, while potentially avoiding increases in add-on medication dosages.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Neurology
ISSN
0340-5354
e-ISSN
1432-1459
Volume of the periodical
270
Issue of the periodical within the volume
5
Country of publishing house
DE - GERMANY
Number of pages
11
Pages from-to
2765-2775
UT code for WoS article
000934834300003
EID of the result in the Scopus database
2-s2.0-85148341331